Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites

Talya L. Dayton 1 2 17 19, Nicolas Alcala 3 17, Laura Moonen 4, Lisanne den Hartigh 1, Veerle Geurts 1, Lise Mangiante 3, Lisa Lap 4, Antonella F.M. Dost 1 2, Joep Beumer 1 2 18, Sonja Levy 5, Rachel S. van Leeuwaarde 6, Wenzel M. Hackeng 7, Kris Samsom 8, Catherine Voegele 3, Alexandra Sexton-Oates 3, Harry Begthel 1, Jeroen Korving 1, Lisa Hillen 4, Lodewijk A.A. Brosens 7, Sylvie Lantuejoul 9 10…Hans Clevers 1 2 18 20

Published: 11 December 2023

Neuroendocrine neoplasms (NENs) comprise well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Treatment options for patients with NENs are limited, in part due to lack of accurate models. We establish patient-derived tumor organoids (PDTOs) from pulmonary NETs and derive PDTOs from an understudied subtype of NEC, large cell neuroendocrine carcinoma (LCNEC), arising from multiple body sites. PDTOs maintain the gene expression patterns, intra-tumoral heterogeneity, and evolutionary processes of parental tumors. Through hypothesis-driven drug sensitivity analyses, we identify ASCL1 as a potential biomarker for response of LCNEC to treatment with BCL-2 inhibitors. Additionally, we discover a dependency on EGF in pulmonary NET PDTOs. Consistent with these findings, we find that, in an independent cohort, approximately 50% of pulmonary NETs express EGFR. This study identifies an actionable vulnerability for a subset of pulmonary NETs, emphasizing the utility of these PDTO models.

Full Access Link: Cancer Cell